Table 1.
The baseline characteristics of the patients in both groups
| TwHF group | Valsartan group | p | |
|---|---|---|---|
| Male: female |
20:14 |
17:14 |
0.805 |
| Age (years) |
51.9 ± 9.8 |
51.0 ± 8.9 |
0.784 |
| Duration of DM (months) |
126.9 ± 68.1 |
106.8 ± 57.3 |
0.270 |
| Duration of DN (months) |
33.8 ± 30.6 |
26.1 ± 28.4 |
0.277 |
| ACEI or ARB treatment before the screening phase (n,%) |
17, 50% |
10, 32.3% |
0.208 |
| Systolic blood pressure (mmHg) |
140.6 ± 15.8 |
138.3 ± 17.1 |
0.515 |
| Diastolic blood pressure (mmHg) |
81.6 ± 11.9 |
84.4 ± 11.1 |
0.233 |
| FBG (mmol/L) |
6.04 ± 1.51 |
6.70 ± 1.62 |
0.092 |
| Glycosylated hemoglobin (%) |
6.26 ± 1.15 |
6.68 ± 1.26 |
0.202 |
| Serum albumin (g/L) |
33.0 ± 5.66 |
33.07 ± 4.74 |
0.988 |
| Total cholesterol (mmol/L) |
6.08 ± 1.96 |
5.92 ± 2.21 |
0.702 |
| Triglycerides (mmol/L) |
1.85 ± 0.83 |
2.50 ± 2.10 |
0.111 |
| Serum creatinine (mg/dl) |
1.92 ± 0.72 |
1.67 ± 0.62 |
0.117 |
| eGFR (ml/min/1.73 m2) |
43.07 ± 21.65 |
47.72 ± 20.34 |
0.377 |
| Serum creatinine > 1.5 mg/dl (%) |
70.6% |
54.8% |
0.210 |
| Urine protein (g/24 h) | 4.99 ± 2.25 | 4.15 ± 1.29 | 0.097 |